1. Home
  2. TPCS vs BOLD Comparison

TPCS vs BOLD Comparison

Compare TPCS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TechPrecision Corporation

TPCS

TechPrecision Corporation

HOLD

Current Price

$3.52

Market Cap

39.4M

Sector

Industrials

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.41

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPCS
BOLD
Founded
1956
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
39.4M
36.5M
IPO Year
2008
2024

Fundamental Metrics

Financial Performance
Metric
TPCS
BOLD
Price
$3.52
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
23.6K
67.2K
Earning Date
02-17-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
64.20
32.47
EPS
N/A
N/A
Revenue
$34,031,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.72
N/A
52 Week Low
$2.88
$0.96
52 Week High
$6.25
$1.68

Technical Indicators

Market Signals
Indicator
TPCS
BOLD
Relative Strength Index (RSI) 32.22 45.14
Support Level $3.40 $1.12
Resistance Level $4.01 $1.53
Average True Range (ATR) 0.15 0.05
MACD -0.05 -0.01
Stochastic Oscillator 7.50 15.77

Price Performance

Historical Comparison
TPCS
BOLD

About TPCS TechPrecision Corporation

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: